Overview

Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate if the duration of treatment of hepatitis C with pegylated interferon and ribavirin can be individualized on the basis of how fast the hepatitis C virus concentration in the blood decreases, and if this is more cost-efficient than standard treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Göteborg University
Collaborators:
Karolinska University Hospital
Lund University Hospital
Sahlgrenska University Hospital, Sweden
Skane University Hospital
Skaraborg Hospital
Sodra Alvsborgs Hospital
Uddevalla Hospital
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin